







BMJ Open Evaluating a model of best practice in primary care led post-diagnostic dementia care: feasibility and acceptability findings from the PriDem study

Sarah Griffiths ¹, Emily Spencer,¹ Katie Flanagan,¹ Aidan O'Keeffe,^{2,3} Rachael Hunter ⁴, Martin Wiegand ⁵, Federica D'Andrea,⁶ Lewis Benjamin,¹ Marie Poole,⁷ Alexander James Hagan ⁷, M Brar,⁷ Jane Wilcock,¹ Kate R Walters ¹, Louise Robinson ⁷, Greta Rait,^{1,3} on behalf of the PriDem Study Team

To cite: Griffiths S, Spencer E, Flanagan K, *et al.* Evaluating a model of best practice in primary care led post-diagnostic dementia care: feasibility and acceptability findings from the PriDem study. *BMJ Open* 2024;**14**:e083175. doi:10.1136/bmjopen-2023-083175

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-083175>).

Received 13 December 2023
Accepted 24 June 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Sarah Griffiths;
s.a.griffiths@ucl.ac.uk

ABSTRACT

Objectives To evaluate the feasibility and acceptability of a primary care-based intervention for improving post-diagnostic dementia care and support (PriDem), and implementation study procedures.

Design A non-randomised, mixed methods, feasibility study.

Setting Seven general practices from four primary care networks (PCNs) in the Northeast and Southeast of England.

Participants We aimed to recruit 80 people with dementia (PWD) and 66 carers

Intervention Clinical Dementia Leads delivered a 12-month intervention in participating PCNs, to develop care systems, build staff capacity and capability, and deliver tailored care and support to PWD and carers.

Outcomes Recruitment and retention rates were measured. A mixed methods process evaluation evaluated feasibility and acceptability of the intervention and study procedures. Using electronic care records, researchers extracted service use data and undertook a dementia care plan audit, preintervention and postintervention, assessing feasibility of measuring the primary implementation outcome: adoption of personalised care planning by participating general practices. Participants completed quality of life, and service use measures at baseline, 4 and 9 months.

Results 60 PWD (75% of recruitment target) and 51 carers (77% of recruitment target) were recruited from seven general practices across four PCNs. Retention rate at 9 months was 70.0% of PWD and 76.5% of carers. The recruitment approach showed potential for including under-represented groups within dementia. Despite implementation challenges, the intervention was feasible and acceptable, and showed early signs of sustainability. Study procedures were feasible and accessible, although researcher capacity was crucial. Participants needed time and support to engage with the study. Care plan audit procedures were feasible and acceptable.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ National Health Service (NHS) Confidentiality Advisory Group support allowed researchers pre-consent access to electronic care notes for recruitment screening and care plan audit data collection. This reduced burden on general practice staff, thereby supporting their involvement in the study.
- ⇒ A proactive, staged recruitment approach including accessible study information and follow-up phone calls, maximised recruitment opportunities.
- ⇒ Researchers developed study procedures with involvement of people with lived experience of dementia: the PriDem Dementia Care Community.
- ⇒ This was a non-randomised design with no control, thereby limiting intervention effectiveness conclusions.
- ⇒ Post-COVID-19 NHS pressures and reduced staff capacity led to challenges in recruiting general practices to the study.

Conclusions The PriDem model is an acceptable and feasible intervention. A definitive study is warranted to fully inform dementia care policy and personalised dementia care planning guidance. Successful strategies to support inclusion of PWD and their carers in future research were developed.

Trial registration number ISRCTN11677384.

BACKGROUND

Dementia is a progressive neurological condition, affecting cognitive functioning, behaviour, emotional well-being and activities of daily living.¹ Over 900 000 people in England and Wales are estimated to have a dementia diagnosis. This figure is projected to rise to 1.7 million by 2040² with annual care costs anticipated to rise from £34.7 billion to

£94.1 billion in that period.³ With incidence levels rising significantly worldwide, dementia is a global public health issue.⁴ Post-diagnostic dementia care, historically situated in secondary care and specialist-led, is often described as inadequate, unaffordable and poorly integrated.^{5,6} International policy^{7,8} and research^{9–12} highlight an urgent need for post-diagnostic care coordination to be led by primary care. This has potential to use existing resources more efficiently and improve timely and tailored access to specialist and community services, thus improving quality of life (QOL) for people with dementia (PWD) and their carers.¹³

Elements of existing primary care led models show potential to improve outcomes for PWD and their families, including embedding dementia-focused health professionals into primary care and building workforce capacity and collaboration.¹⁰ Informed by evidence reviews and qualitative research, the 5-year PRiMary care led post-diagnostic DEMentia care (PriDem) research programme developed a primary care led complex intervention to improve post-diagnostic dementia care and support and tested this in a feasibility and implementation study.¹⁴

The intervention involves Clinical Dementia Leads (CDLs) situated within primary care, supporting improvements to dementia care systems, delivery of holistic tailored care, and workforce capacity building.

In line with Medical Research Council guidance,^{15,16} we tested the PriDem intervention in practice to assess the feasibility and acceptability of the intervention and evaluation methods, and to support decisions about a future large-scale implementation study. As PWD are often excluded from research about their needs, especially when they have no informal carer to support their inclusion,¹⁷ we examined methods of recruiting and retaining PWD, including those who lack capacity to consent.

AIMS

We aimed to evaluate the feasibility and acceptability of the PriDem intervention and study processes, with outcomes measured through (a) recruited samples of PWD, carers and professionals and (b) a general audit sample of PWD on general practice dementia registers, preintervention and postintervention, accessed through electronic care records.

Primary feasibility and acceptability objectives

1. Evaluate recruitment and retention rates at primary care network (PCN), general practice and patient/carer levels.
2. Assess acceptability and engagement with the intervention and implementation study procedures.
3. Assess feasibility of service use data collection through electronic records, by measuring the proportion of notes available for review.

Secondary feasibility and acceptability objectives

1. Measure the number of patient records reviewed in a dementia care plan audit (audit sample).

2. Assess feasibility and acceptability of recruiting and training CDLs and embedding them within existing care pathways/service delivery models.
3. Determine intervention fidelity.
4. Identify resource requirements to access, collect and analyse study data.
5. Evaluate acceptability and appropriateness of the primary implementation outcome: an increase in the number of PWD with a personalised care plan at recruited general practices.

METHODS

Study design and procedures

A non-randomised, mixed methods, feasibility and implementation study was conducted. Detailed methods are described in the study protocol¹⁸ (see online supplemental file 1 for original protocol). Study reporting has been informed by guidelines for reporting non-randomised pilot and feasibility studies¹⁹ and Consolidated Standards of Reporting Trials extension guidelines.²⁰

Patient and public involvement

Researchers worked with a stakeholder group of PWD, current and former carers, and professionals—the PriDem ‘Dementia Care Community’ (DCC)—throughout the PriDem programme. During the feasibility study, two PWD, two carers, eight former carers and three homecare professionals from the DCC advised on data collection methods (including piloting outcome measures) and the National Health Service (NHS) Confidentiality Advisory Group (CAG) application.

Sites and participants

We aimed to conduct the study within four PCNs; two in Northeast (NE) and two in the Southeast (SE) England (see sample size below).

PWD were eligible if they were: over 18 years old, registered with a participating general practice, diagnosed with dementia, community dwelling, able to consent or able to be recruited via personal consultee (a relative or friend who can advise on what the person’s wishes would be if they were able to consent for themselves).²¹ Carers were eligible if they were over 18 years old, caring for a person with dementia who had agreed to take part, English speaking, and willing and able to provide informed consent. Both PWD and carers were ineligible if judged inappropriate for the study by their general practitioner (GP) (eg, due to current life events such as a bereavement) or had an advance statement indicating they did not wish to participate in research. Eligible PWD were approached first. Those who agreed to take part were then asked if they would like a carer to take part alongside them. Where carers were the primary contact, due to the person having more advanced dementia, we invited them to take part alongside the person with dementia or nominate an alternative carer (if any) to be invited.

The study took place during increasing demands on general practice staff due to COVID-19. To reduce burden

on participating practices, researchers undertook eligibility screening of general practice dementia registers, and mailout activities with NHS CAG support. The mailout was sent to all eligible participants and included an accessible written Patient Information Sheet (see <https://tinyurl.com/585rrwh>) with audio and visual versions available on request. Non-responders were contacted by telephone to provide an opportunity to find out about the study and opt in or out. Researchers informed general practice teams of those who were uncontactable after three attempts so that GPs could check for unmet needs and alert those patients to the PriDem study if appropriate.

Researchers used a protocol adapted from the British Psychological Society to determine capacity to consent (<https://www.bps.org.uk/guideline/conducting-research-people-not-having-capacity-consent-their-participation>). Where potential participants were judged to lack capacity to consent to take part, a family member or friend acted as personal consultee. Participants who self-consented identified a person who could be approached to act as a consultee should they lose capacity later in the study.

Participating sites and participants had exposure to the intervention over a 12-month period.

PriDem intervention

The intervention aimed to promote sustainable change in post-diagnostic care for PWD and carers, led by primary care. A manualised intervention was developed,^{14 22} focusing on three interlinked intervention strands:

1. Developing systems—mapping local dementia services, reviewing referral and transition processes.
2. Delivering tailored care and support—working with general practice teams to develop tailored approaches and resources to optimise annual dementia reviews. This is an NHS Quality and Outcomes Framework (QOF) indicator for dementia care²³ (a voluntary financial incentive programme of care indicators, for general practices in England). Improving personalised dementia care planning.²⁴ Providing advice and management for PWD with complex needs.
3. Building capacity and capability—upskilling the workforce.

Two CDLs, one in the SE and one in the NE, led the intervention. Both CDLs were senior nurses with more than ten years of experience in frailty and dementia. They undertook a bespoke PriDem training programme and were supported by ongoing clinical supervision with a highly experienced specialist dementia nurse, and intervention supervision with researchers and the clinical supervisor.

Data collection

For the recruited PWD/carer sample, a range of data was collected, shown in [table 1](#), with follow-up times for questionnaires at baseline, 4 months and 9 months. Service use data was also collected for this sample, covering

the 12-month period prior to the intervention and the 12-month period from the start of the intervention.

For the care plan audit sample, demographic data and outcomes related to dementia care plans were collected for 2018–2019 and 2022–2023 QOF years, with separate audit samples for each period.

Researchers kept a written log of their reflections following participant visits.

The primary outcome was the proportion of personalised care plans in each of the 2018–2019 and 2022–2023 QOF years. Secondary outcomes included QOL and well-being outcomes (eg, DEMQOL, EQ-5D-5L, NPI), and service use, as detailed in [table 1](#). All researchers undertook the same training in completing standardised outcome measures and were guided by a researcher handbook. They ascertained the capacity of PWD to respond to questionnaires based on their capacity assessments, informal observations and conversations with a carer. Formal reliability measures were not undertaken. Based on piloting outcome measures with PWD and carers, we estimated that measures to be carried out with PWD would take 30–45 min and those with carers, 60–75 min (a total of 90–120 min). Researchers took a person-centred approach to data collection, arranging remote or in person meetings depending on participant preferences, and offering a series of visits where appropriate to counteract fatigue.

Sample size

For the care plan audit, it was anticipated that approximately 40% of people diagnosed with dementia had a personalised care plan, based on a pilot audit carried out by clinical research team members. A sample of 215 PWD is sufficient to detect an increase of at least 0.1 in the proportion of PWD with a personalised care plan, from a null hypothesis of 0.4, using a one-sided, one-sample Z-test with a power of 90% and a 5% significance level.

For the recruited sample, we anticipated that up to four PCNs would participate in the study and expected to recruit up to 80 PWD and 66 carers during the first 4 months of the study.

As this was a feasibility study, a power-based formal sample size calculation related to a hypothesis test of interest was not appropriate. Although sample size recommendations may vary from study-to-study because of specific study aims, it is generally accepted that a sample size of 30 or more participants is suitable to provide a reasonable level of precision if estimating measures of interest.^{25 26} We aimed to recruit approximately 20 people living with dementia at each PCN to give a sample of up to 80 participants with approximate balance between PCNs.

We aimed for the PCNs to be spread equally between the NE and SE regions to provide a geographical and demographic spread of patient types, therefore we aimed to recruit two PCNs from each region.

Table 1 Data collection sources

Outcome	Measures	Point of collection (m: months)			
		2018–2019 QOF year	12 m preintervention phase	Baseline	12 m intervention phase
People with dementia					
Cognitive screening	Montreal Cognitive Assessment (MoCA Blind) ³⁹ ; a test of cognitive abilities. This version can be used in person or via the phone	x			
Quality of life and well-being	Self-rating scales completed by people with dementia: Dementia Quality of Life measure (DEMQOL), ⁴⁰ and physical and mental health measure EQ-5D-5L ⁴¹	x	x	x	
	Completed by carers: proxy DEMQOL (carer ratings of the PWD's quality of life) and EQ-5D-5L (carer rating of the PWD's health). Neuropsychiatric Inventory ⁴² : carer rating of the presence/absence of observed neuropsychiatric symptoms in the PWD	x	x	x	
Service use	Participant service use data (contacts with health, social and voluntary sector) extracted from electronic medical records	x			x
	Completed by carers: Client Services Receipt Inventory (CSRI), ⁴³ adapted from IMTA Valuation of Informal Care Questionnaire (iVICQ). ⁴⁴ This was used to collect data on the social services used by PWD (eg, social worker contacts and home care)	x	x	x	
Primary outcome: adoption of personalised care planning by participating general practice	Care plan audit of electronic care records, measuring presence/absence of personalised care plans. Preintervention QOF year 2018–2019 compared with intervention year 2022–2023. Random sample of 215 registered patients with dementia diagnosis living at home at beginning of each audit period (<i>not restricted to recruited participants</i>). Stratified sampling based on estimated number of eligible patients on each practice register. <i>Individual patients not followed up</i>	x			x
Description of sample	<i>Participant demographics:</i> (a) age; (b) gender; (c) ethnicity; (d) site (NE or SE); (e) relationship of PWD to carer; (f) type of dementia; (g) time since dementia diagnosis; (h) social deprivation score (using postcode-based Index of Multiple Deprivation (IMD) quintile)	x			
Carers					
Quality of life and well-being	Self-rating scales completed by carers: Hospital Anxiety and Depression Scale (HADS), ⁴⁵ measuring the presence of carer depressions and/or anxiety, Carer-DEMQOL, ⁴⁶ Measuring the carer's quality of life in relation to the dementia and EQ-5D-5L, ⁴¹ measuring the carer's physical and mental health	x	x	x	
	PWD, people with dementia; QOF, Quality and Outcomes Framework.				

Data analysis

Participants' baseline characteristics were summarised using appropriate statistics, with categorical variables reported as counts and percentages and continuous variables using means, SD and ranges.

The primary outcome was analysed by reporting the proportion of people living with dementia who have a personalised care plan in place, together with an associated 95% CI, for each of the 2018–2019 audit and 2022–2023 audit periods (ie, preintervention and postintervention). The minimum requirement for a care plan to be judged as personalised was the presence of the PWD and/or carer when agreeing on the plan (see Griffiths *et al*¹⁸ for more detailed information). A one-sample Z-test was used to test the null hypothesis that the proportion of PWD who have a personalised care plan is 0.4, against a one-sided alternative that this proportion is >0.4, for each of the 2018–2019 and 2022–2023 audit years.

For the recruited sample, secondary outcomes are reported at baseline and at each follow-up time using appropriate summary statistics. All analyses were complete case with no adjustment for missing data. Numbers of withdrawals from the study are reported with reasons.

Process evaluation

A mixed methods process evaluation aimed to describe factors influencing implementation of the intervention in practice. Qualitative data comprised semi-structured interviews with an opportunistic sample of 14 PWD and 16 carers recruited to the study, who had varying levels of engagement with initiatives driven by the intervention, based on our conversations with them or on CDL feedback. Interview topic guides for each participant group can be found in online supplemental files 2–9. In addition, we collected 14 observation fieldnotes of the CDL delivering formal or informal training or in multi-disciplinary team meetings. Codebook thematic analysis²⁷ was used to develop themes relevant to implementation barriers and facilitators, with normalisation process theory (NPT)²⁸ used as an analytic lens. Detailed qualitative process evaluation findings will be reported elsewhere.

A checklist of 15 key intervention activities (Practice Engagement Log), was completed at one timepoint, at the intervention end, in discussion with CDLs to assess fidelity of engagement by general practices with the intervention using descriptive statistics. The 15 activities were those outlined in the intervention manual, including practice staff engaging in 'developing a map of local dementia services, for interested stakeholders', 'testing PriDem dementia review and care planning resources' and 'receiving training delivered/arranged by the CDL'.

RESULTS

Primary feasibility outcomes

Rates of recruitment and retention at follow-up

NHS sites

The target four PCNs were recruited. Within these PCNs, seven GP practices were recruited: three in the SE (from one PCN) and four in the NE (spanning three PCNs). An

additional practice agreed to take part but withdrew after a Site Initiation Visit, citing lack of capacity to engage with the intervention. Staff had not fully appreciated the practice-led nature of the intervention, with the CDL supporting systems improvements rather than directly addressing the dementia caseload.

Participants: PWD and carers

Recruitment duration was 19 weeks in the SE and 14 weeks in the NE. We recruited 60 PWD (28 in the SE; 32 in the NE—75% of recruitment target) and 51 carers (23 in the SE; 28 in the NE—77% of recruitment target). Of patients screened, 50.4% (291) were eligible. Of those eligible, 20.6% (60) were recruited to the study (figure 1).

The sample included those who are typically under-represented in dementia research.¹² Almost half (44.8%) of PWD were recruited via consultee declaration (a form stating a personal consultee's advice on whether the PWD would wish to take part) (table 2). This demonstrates potential to involve people with more advanced dementia in research, reflected in Montreal Cognitive Assessment scores, which indicated moderate to severe cognitive impairment. Over a quarter (25.9%) of participants with dementia lived alone and 15.5% did not have a carer participating alongside. 15.5% of PWD and 22.4% of carers were from non-white ethnic backgrounds.

Withdrawals

Withdrawals by study stage are shown in figure 1. Overall retention rate at 9-month follow-up was 70.0% of PWD and 76.5% carers. The most common reasons for withdrawal were the person with dementia had moved into a care home or died. One dyad lost to baseline (figure 1) were found to be ineligible only following a 9-month follow-up. The patient had been on the general practice dementia register but was later found to have no formal diagnosis. One person with dementia withdrew as they were upset with a lack of support from their general practice and cynical that anything would change. This echoed some of the comments from people opting out during the recruitment phase.

Acceptability and engagement with the intervention and implementation study procedures

Intervention

Engagement with the intervention was measured using the Practice Engagement Log (table 1). Engagement varied between practices, from one practice engaging with only 6 of the 15 intervention activities, to three practices engaging with 14 activities (median=13). The qualitative process evaluation (to be reported in a future publication) provided a nuanced understanding of engagement. For example, although both CDLs reported via the log that all practices had engaged in dementia training, there were important differences identified through the qualitative data analysis. In one region, training was delivered to a wide range of staff (eg, receptionists, GPs, social prescribers), and in the other region social prescribers




Figure 1 Consolidated Standards of Reporting Trials diagram—recruitment and retention rates for the seven general practices. GP, general practitioner; NE, Northeast; SE, Southeast.

Table 2 Participant characteristics

Characteristic		PWD	Carers
Age (years) mean (SD) (min, max), n		81.4 (7.3) (61, 97), n=58	66.3 (32,95); n=48
Gender N (%)	Male	33 (56.9)	12 (24.5)
	Female	25 (43.1)	37 (24.5)
Region N (%)	Northeast	30 (51.7)	26 (53.1)
	Southeast	28 (48.3)	23 (46.9)
Dementia diagnosis N (%)	Alzheimer's	43 (74.1)	
	Lewy Body	1 (1.7)	
	Vascular	1 (1.7)	
	Mixed	4 (6.9)	
	Other	2 (3.5)	
	Not known	4 (6.9)	
	Missing	3 (5.2)	
MOCA score mean (SD) (min, max), n		10.6 (4.3) (2, 19) n=49	
Time since dementia diagnosis (years) mean (SD) (min, max), n		2.8 (2.6) (0.3, 9.5), n=47	
Deprivation score (IMD quintile) N (%)	5	22 (37.9)	
	4	12 (20.7)	
	3	11 (19.0)	
	2	3 (5.2)	
	1	7 (12.0)	
	Missing	3 (5.2)	
Approach to consent N (%)	Self-consent	32 (5.2)	
	Consultee	26 (44.8)	
	With carer	49 (84.5)	
Participating with/without carer N (%) Data available: 58 P	Without carer	9 (15.5)	
Ethnicity N (%)	White	49 (84.5)	38 (77.6)
	Asian/Asian British	4 (6.9)	5 (10.2)
	Black, African, Caribbean or Black British	1 (1.7)	1 (2.0)
	Mixed or multiple ethnic groups	1 (1.7)	1 (2.0)
	Other ethnic group	3 (5.2)	4 (8.2)
Marital status N (%)	Married	32 (55.2)	38 (77.6)
	Widowed	16 (27.6)	0
	Divorced	6 (10.3)	4 (8.2)
	Single (never married)	4 (6.9)	2 (4.1)
	Cohabiting	0	3 (6.0)
	Separated	0	2 (4.1)
Living status N (%)	Lives with spouse or partner only	28 (48.3)	39 (79.6)
	Lives with other family (not spouse or partner)	9 (15.5)	8 (16.3)
	Lives with spouse/partner and other family	1 (1.7)	2 (4.1)
	Lives with other (not family)	1 (1.7)	0
	Lives with other family (not spouse or partner) and other (not family)	1 (1.7)	0
	Lives alone	15 (25.9)	0
	Unknown	3 (5.2)	0

Continued

**Table 2** Continued

Characteristic		PWD	Carers
Relationship to carer N (%)	Spouse	23 (39.7)	
	Son/daughter	18 (31.1)	
	Son/daughter in law	2 (3.4)	
	Brother/ Sister	3 (5.2)	
	Friend	2 (3.4)	
	Neighbour	1 (1.7)	
	Participated without carer	9 (15.5)	

IMD, Index of Multiple Deprivation; MOCA, Montreal Cognitive Assessment²⁴; n, number; N, total number; P, participants; PWD, people with dementia.

were the focus. Social prescribers are primary care practitioners whose role is to connect people with social and community activities and agencies, to promote physical and mental health (<https://socialprescribingacademy.org.uk/what-is-social-prescribing/>).

Assessment of study procedures

Recruiting and retaining PWD and carers

Participants predominantly opted for in-person rather than remote meetings with researchers. Some found these tiring: 'I know all these questions have got to be done but it was far too long even I was weary' (Interview with carer). However, most reported that in-person visits brought much-needed conversation and company in the post-COVID-19 restrictions era. 10 of 49 carers completed some questionnaires as an online survey, after meeting a researcher in person and found this an acceptable option.

10 full-time and part-time trained researchers were involved in visiting participants, across the two regions, with various backgrounds including clinical (speech and language therapy and clinical psychology), and research in ageing populations and primary care. Researchers routinely phoned participants the day before a scheduled visit to check the visit was still convenient and as a memory prompt. We aimed for consistency, with a named researcher carrying out all baseline and follow-up visits with an individual person with dementia and their carer, where possible. This helped build relationships and trust.

Recruiting and retaining practice teams

Practice teams valued researcher efforts to reduce burden: 'We didn't have to hold your hands; you knew what you were doing, and we just let you get on with it' (Interview with care co-ordinator, general practice 02). Researcher-staff relationships developed over time, facilitating study engagement: '... the way you have collaborated with us I think, has been really receptive ... I think we've bounced things backwards and forwards really nicely, you guys have adapted to ... the ... individualised needs of the different practices' (Interview with GP, general practice 03).

Some practice staff remained disengaged despite their practice's participation. Research was seen as an additional burden in the context of an overwhelmed

workforce with limited resources and little financial incentive. The National Institute for Health Research Clinical Research Network provided research support costs for sites; however, these rates were questioned as not factoring in meetings with the research team prior to agreeing to take part. One CDL commented that a GP was initially reluctant to engage: 'they won't do anything new unless it's for money' but that this stance changed completely once the intervention's potential was demonstrated through tangible changes to care planning systems.

Participant experiences of outcome measures

We created written cue cards, to support participants (both PWD and carers) in responding to multiple choice questionnaire items, which they found helpful. These were used as a visual prompt to aid recall, to help stay on track and to allow participants to respond privately by pointing, when worried a relative could hear their responses.

DEMQOL¹⁹ and EQ-5D-5L²⁰ responses were sometimes skewed towards a 'no problem' presentation, compared with lower carer proxy ratings, a pattern previously reported in the literature.^{29 30} It was usually discussed with the carer and a decision made about whether to complete the same measures at follow-up. Carers found it increasingly problematic to complete proxy QOL measures the more advanced the dementia, expressing that they could not guess the person with dementia's emotions. Despite researchers being sensitive to participant needs, carer distress was common. However, carers typically wished to continue with questionnaires, finding it helpful to talk about their caring experiences:

I could imagine some [researchers] might hold themselves outside it, "I can't get involved" But ... it's such a sad and difficult thing ... so if somebody doesn't say to you, "It is tough", or, "Oh yes, I can see that's tricky", whatever it might be, so I do find that helpful, just that acknowledgement. (Interview with carer)

Proportion of PWD whose notes were reviewed for service use data

Baseline service use data collection was feasible. This was collected for 55 PWD (91.6% of participants) and 12-month follow-up data collected for 53 PWD (88.3%).

Secondary feasibility results

Number of patient records reviewed in the dementia care plan audit

For the baseline care plan audit, there was a lower than estimated number of eligible patients on the dementia registers for four of the seven practices. We over-recruited in two practices until all potentially eligible participants had been included. The stratified sampling strategy for the follow-up audit was successful. At baseline, 179 patient records were audited (83.7% target) and at follow-up, 215 (100% target).

Feasibility and acceptability of engaging and training clinical dementia specialists and embedding within existing care pathways and models of service delivery

Engaging and training the CDLs

It was challenging to recruit to short-term (12 months) CDL posts, in the context of NHS staff shortages. Highlighting secondment and job share opportunities helped attract candidates, as did advertising locally through NHS networks in project localities.

The PriDem intervention manual and training were well received by CDLs and the clinical supervisor. Support provided beyond initial training through intervention supervision and clinical supervision were thought to be essential by CDLs and supervisors: ‘... primary care can be very challenging it’s valuing them as individuals and making sure their well-being is maintained within what is sometimes a really complex situation’ (Interview with clinical supervisor).

Embedding CDLs in general practice

CDLs experienced difficulties becoming embedded in practices, especially as post-COVID-19, structures for team face-to-face meetings had yet to be reintroduced: ‘The challenges have been ... having to persuade people ... not having an office base ... or a visible presence. Working from home has been a major challenge’ (Interview with CDL). To combat these challenges, they used their clinical backgrounds as a ‘hook’ to engage practice staff. For instance, one CDL used evidence based PriDem annual dementia review and care plan templates with a patient, sharing their learning with a GP, which led to a discussion about annual dementia review systems in the practice. One CDL reflected that mapping local dementia services involved making links with a range of service providers. This led to building relationships with commissioners, becoming embedded in dementia pathway planning groups, working across silos and bringing practitioners together.

Intervention sustainability

Towards the intervention end, CDLs worked with practice teams towards sustainability. Two practices in the SE

had set-up ‘One Stop Shop Dementia Review Clinics’ for instance, whereby several PWD and carers attended a practice on the same day for a review with their GP, other practice team members (eg, practice nurse, social prescriber, dementia advisor) and staff from Age UK. This innovation sustained beyond the intervention lifetime.

Intervention fidelity

The intervention was delivered over the planned 12 months. Although qualitative data suggest the intervention was delivered broadly as intended across research sites, intervention flexibility meant some elements were stretched, risking fidelity to intervention aims. For example, in some cases patient-facing aspects of CDL roles were extended beyond intervention aims, or delivery of staff training minimised.

Resource requirements to access, collect and analyse data

From initial meetings with PCNs to recruiting seven general practices, it took 5 months.

Although outcome measures were trialled with our DCC members, completion time was underestimated. Carers needed longer than anticipated to expand on multiple choice responses and verbalise emotional responses. Often, consent was obtained, and measures completed over two or three visits, with each visit taking over 2 hours. Participants valued having time to build relationships with researchers and enjoyed sharing refreshments with them; an important element of trust building and retention. Therefore, data collection was resource intensive.

Although researchers received informal training and support, including shadowing of more experienced researchers, and informal debriefing following participant visits, study set-up delays led to a condensed timeline. With recruitment a priority, there was less inbuilt researcher training and formal debriefing (given the emotional impact often experienced by researchers) than would have ideally been incorporated. There were also limited resources for peer visiting, although when this occurred, researchers found it supportive and efficient.

Acceptability and appropriateness of the primary implementation outcome

Qualitative interviews revealed that personalised care was of great importance to participants. There were challenges however in operationalising the concept of ‘personalised care planning’. Informed by literature, existing care plan templates, national policy²⁴ and key components of post-diagnostic care,¹⁴ we worked with the DCC to develop an acceptable data extraction form (see Griffiths *et al*¹⁸ for detailed methods). General practices were able to provide dementia registers for the baseline and follow-up QOF years.

Safety

This was a low-risk intervention. There were 21 serious adverse events (SAEs), comprising hospital admissions (n=17) and deaths (n=4). No SAEs were related to the intervention. One non-SAE was judged possibly related

to the intervention: a person with dementia experienced increased anxiety and depression, potentially precipitated by change in medication following an annual dementia review. Following medical assessment, their medications were adjusted, and they recovered.

RESULTS: PRIMARY OUTCOME

A one-sample Z-test of the null hypothesis that the true proportion of people with a personalised care plan is 0.4 was carried out for each audit year. While 37.4% (95% CI 30.3% to 44.5%), $p=0.759$ of patients had a personalised care plan in place during the preintervention audit year (2018–2019), this increased substantially to 64.7% (95% CI 58.3% to 71.0%), $p<0.0001$ in the intervention year (2022–2023). Those without any form of care plan (whether personalised or non-personalised) reduced from 45.8% (95% CI 38.5% to 53.1%) preintervention to 22.3% (95% CI 16.8% to 27.9%) of PWD.

RESULTS: SECONDARY OUTCOMES

The results of patient and carer questionnaires remained relatively consistent from baseline to 9 months (table 3), and there were no marked changes in service use.

DISCUSSION

Intervention acceptability and feasibility

Recent research has called for an exploration of post-diagnostic dementia care models delivered by generalist, rather than specialist services.³¹ This current study has demonstrated that the PriDem intervention, designed to support and upskill a non-specialist primary care multi-disciplinary workforce to improve dementia care and support systems, is both feasible and acceptable. General practice capacity can be a barrier to implementing such primary care led interventions.¹⁰ However, we found that primary care staff engaged with most elements of the intervention, including staff training, and developing new approaches to dementia reviews and care planning, although the approach to this differed across practices. Potentially, this level of engagement was due to practices with existing enthusiasm for developing dementia care expertise, self-selecting for the study. This is underlined by one practice pulling out of the study due to the realisation that staff were required to drive innovations, although with support from a CDL.

It was possible to recruit and retain nurses with dementia expertise as CDLs to deliver the intervention over 12 months, however clinical supervision from a highly experienced dementia specialist is essential and support is required to enable CDLs to become established within primary care teams, including the provision of physical space. Further in-depth findings on intervention acceptability and its impact on personalised care planning will be published elsewhere.

It has been recommended that future national dementia guidelines should place greater emphasis on multi-disciplinary team collaboration³² and that future interventions consider integration of post-diagnostic care with diagnostic services in a whole systems approach.³¹ These elements should be explored when rolling out the PriDem intervention in a larger implementation study. This study has focused on community dwelling PWD. Future research might also explore the benefits of introducing a CDL in the social care sector to support systems for dementia care planning in care homes, as research in this area largely focuses on planning for end-of-life care,³³ with limited research on more holistic care planning.³⁴

Acceptability and feasibility of study procedures

Taking a proactive and staged recruitment approach led to meeting 75% of our recruitment target of PWD. This approach supported inclusion of PWD in research but also showed potential for inclusion of under-represented groups within dementia research, such as people from minority ethnic communities, people living alone with dementia and those with advanced dementia. Retention rates were comparable to those reported in dementia trials.³⁵

Study procedures were feasible and largely acceptable, although there is a need for consideration of participant emotional burden, fatigue and acceptability regarding outcome measures. Researcher capacity for recruitment, retention, obtaining individual-level data and qualitative analysis should not be underestimated. Participants need time and support to engage and build relationships with researchers.

Limitations and strengths of this study

This was a small-scale feasibility study; therefore, no rigorous conclusions can be drawn regarding intervention effectiveness. A key reason for carers opting out was carer strain, suggesting a limitation of recruitment approach. In a future study, funding for replacement care should be incorporated to support carer participation. Although we worked alongside our patient and public involvement group (DCC) to develop study information resources, we would revisit these to explore ways of further enhancing accessibility, for instance, developing further strategies to alleviate concerns of PWD about participating (eg, being anxious about talking with strangers). It is also important for researchers to be sensitive to PWD and carers with histories of receiving poor/no dementia care, who may be cynical about joining or continuing to participate in a dementia care study, and to develop strategies to support their engagement.

The study has highlighted limitations and a lack of acceptability relating to standardised dementia outcome measures, including carers reporting discomfort with completing proxy measures. This suggests a need to reconsider which outcomes are important and acceptable to PWD and carers and how they should be measured in a future study. Aligning with our experiences, a recently

Table 3 Patient and carer questionnaire results

Measure	Baseline	4 months	9 months
PWD ratings of own health and well-being (n=number of PWD who completed questionnaires)			
DEMQOL score—mean (SD) (min, max)	n=48 87.9 (16.1) (39, 110)	n=42 87.9 (14.8) (55, 110)	n=38 88.0 (14.6) (56, 109)
DEMQOL overall quality of life (QOL)—n (%)	n=48 Very good: 14 (29.2) Good: 19 (39.6) Fair: 11 (22.9) Poor: 4 (8.3)	n=41 Very good: 8 (19.5) Good: 18 (43.9) Fair: 12 (29.3) Poor: 3 (7.3)	n=38 Very good: 9 (23.7) Good: 18 (47.4) Fair: 9 (23.7) Poor: 2 (5.2)
EQ-5D-5L EUROQOL index score (England) ⁴⁷ - Mean (SD) (Min., Max.)	n=48 0.79 (0.19) (0.30, 1)	n=42 0.77 (0.19) (0.30, 1)	n=38 0.80 (0.22) (0.08, 1)
Carer ratings of PWD health and well-being (n=number of carers who completed questionnaires)			
DEMQOL Proxy—mean (SD) (min, max)	n=49 96.09 (12.7) (67.8, 122)	n=42 96.23 (13.4) (62, 121)	n=32 92.19 (14.9) (57.1, 120)
DEMQOL-Proxy overall quality of life of PWD—n (%)	n=49 Very good: 7 (14.3) Good: 23 (46.9) Fair: 14 (28.6) Poor: 5 (10.2)	n=43 Very good: 6 (14.0) Good: 17 (39.5) Fair: 13 (30.2) Poor: 7 (16.3)	n=32 Very good: 4 (12.5) Good: 10 (31.3) Fair: 14 (43.7) Poor: 4 (12.5)
EQ5D-5L Proxy EUROQOL index score (England) ⁴⁷ —mean (SD) (min, max)	n=49 0.63 (0.23) (0.03, 1)	n=42 0.64 (0.29) (-0.16, 1)	n=31 0.66 (0.22) (0.10, 1)
Neuropsychiatric Inventory scores (total, carer distress)—mean (SD) (min, max)	n=49 Total: 17.61 (16.7) (0, 93) Distress: 8.71 (7.1) (0, 38)	n=43 Total: 17.12 (14.1) (0, 52) Distress: 8.42 (7.4) (0, 28)	n=33 Total: 14.0 (12.1) (0, 46) Distress: 8.45 (6.0) (0, 21)
Carer ratings of own health and well-being (n=number of carers who completed questionnaires)			
HADS Anxiety and Depression Scale—mean (SD) (min, max)	Anxiety (n=49): 7.02 (3.8) (1, 16) Depression (n=49): 4.84 (3.4) (0, 14)	Anxiety (n=43): 7.30 (1, 3, 8, 15) Depression (n=40): 4.80 (3.5) (0, 16)	Anxiety (n=35): 6.83 (3.9) (0, 15) Depression (n=31): 4.26 (3.1) (0, 14)
Carer DEMQOL—mean (SD) (min, max)	n=49 87.7 (18.7) (46.8, 124)	n=42 90.7 (17.2) (57, 136)	n=29 91.9 (17.3) (51.7, 123.3)
Carer EQ5D-5L EUROQOL index score (England)—mean (SD) (min, max)	n=49 0.85 (0.15) (0.42, 1)	n=43 0.84 (0.13) (0.39, 1)	n=35 0.86 (0.13) (0.41, 1)
PWD, people with dementia.			

published global consensus did not list the DemQol as one of several ideal measures of QOL in dementia, including proxy and carer versions.³⁶

Working with our DCC was a key strength, essential to ensuring accessible study procedures which took account of peoples' everyday lives. However, this still led to an underestimation of time needed to recruit people to the study and conduct outcome measures, which often took place over several visits. Recruiting general practices was challenging. The study took place when general practices

were engaged in managing the COVID-19 vaccination programme and NHS Recovery Plan.³⁷ Having NHS CAG support in place allowed researchers to carry out pre-consent recruitment and care plan audit activities, thereby reducing burden on practice staff and supporting study engagement. A generous study lead-in time is needed in future research to build relationships with potential sites, ensure they understand the intervention, problem solve how best to support their involvement and recruit clinicians to deliver the intervention.



CONCLUSIONS

Despite implementation challenges, our findings indicate that a feasible and acceptable primary care led intervention showed early signs of sustainability, such as improving consistency and quality of annual dementia reviews. The positive recruitment, retention and primary outcome results suggest a definitive study is warranted. Funding for a larger scale implementation study should include adequate time for relationship-building with sites and participants and should consider researcher capacity, training and support. Such a study could inform future National Institute for Health and Care Excellence guidelines,³⁸ commissioning decisions and NHS England recommendations for personalised dementia care planning.¹⁷ This would improve access to timely and tailored dementia care and support across the dementia trajectory, for PWD and their carers, thereby improving QOL.

Author affiliations

¹Research Department of Population Health and Primary Care, Institute of Epidemiology & Health, Faculty of Population Health Sciences, UCL, London, UK

²School of Mathematical Sciences, University of Nottingham, Nottingham, UK

³PRIEMT Clinical Trials Unit, UCL, London, UK

⁴Applied Health Research, Institute of Epidemiology & Health, Faculty of Population Health Sciences, UCL, London, UK

⁵Department of Statistical Science, UCL, London, UK

⁶School of Biomedical Sciences, University of West London, London, UK

⁷Faculty of Medical Sciences, Population Health Sciences Institute, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK

Acknowledgements We would like to thank: the people with dementia, carers, general practices and professionals who participated in this research; the PriDem Dementia Care Community (DCC); researchers Claire Bamford, Alison Wheatley, Greta Brunskill; Angela Mattison; Robyn Barker, Rachel Watson and Zena Aldridge.

Collaborators This study was carried out as part of the Alzheimer's Society funded PriDem Programme. The PriDem Research Team also includes Alistair Burns, Emily Evans, Derek King, Martin Knapp, Revd Doug Lewins, Sube Banerjee, Jill Manthorpe, Louise Allen, Sue Tucker and Raphael Wittenberg.

Contributors All authors meet ICMJE criteria for authorship. SG wrote the first draft and was lead author on subsequent drafts. GR, ES and KF refined the first draft. All other authors commented on later drafts. AO, JW, KRW, LR and GR were involved in the conception of the original PriDem study protocol. SG, ES, KF, FD, LB, MP, AJH and MB collected data. AO, MW and RH analysed statistical data. Qualitative data analysis was led by ES in collaboration with KF and oversight from SG. GR, as chief investigator and guarantor, approved the final draft.

Funding This work was supported by Alzheimer's Society (grant number AS-PR2-16-005). SG receives support from the NIHR Applied Research Collaboration North Thames and Alzheimer's Society through a post-doctoral fellowship. ES receives support from Alzheimer's Society doctoral project grant 544 (AS-PhD-19b-006). MP receives support from the NIHR Applied Research Collaboration Northeast and North Cumbria and Alzheimer's Society through a post-doctoral fellowship.

Disclaimer The views expressed are those of the authors and not necessarily those of the funders, NHS or Department of Health and Social Care.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval Ethical approval for the study was obtained from Wales REC4 of the National Research Ethics Service (21/WA/0267). NHS Confidentiality Advisory Group (21/CAG/0182) recommended that support under Regulation 5 of the Health Service (control of patient information) Regulations 2002 ('section 251 support') was given for the processing of patient information, enabling researchers to access

specific patient data without prior informed consent. Recruited participants gave written or verbal informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The deidentified data that support the findings of this study were collected through and are held by University College London. Restrictions on the availability of these data apply, which were used under license for the current study, and are not publicly available. Quantitative data is available from the authors upon reasonable request with permission of Professor Greta Rait (g.rait@ucl.ac.uk). Qualitative data, which has been pseudonymised rather than anonymised, will not be available. Requests to use data will be submitted on a standard form and reviewed by a committee prior to data-sharing agreements being developed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Sarah Griffiths <http://orcid.org/0000-0002-2652-3163>

Rachael Hunter <http://orcid.org/0000-0002-7447-8934>

Martin Wiegand <http://orcid.org/0000-0003-0276-658X>

Alexander James Hagan <http://orcid.org/0000-0002-3622-3949>

Kate R Walters <http://orcid.org/0000-0003-2173-2430>

Louise Robinson <http://orcid.org/0000-0003-0209-2503>

REFERENCES

- 1 NHS. About Dementia: Dementia Guide, 2020. Available: <https://www.nhs.uk/conditions/dementia/about>
- 2 Chen Y, Badosz P, Stoye G, *et al*. Dementia incidence trend in England and Wales, 2002–19, and projection for dementia burden to 2040: analysis of data from the English longitudinal study of ageing. *Lancet Public Health* -> *Lancet Public Health* 2023;8:e859–67.
- 3 Wittenberg R, Hu B, Barraza-Araiza L, *et al*. Projections of older people with dementia and costs of dementia care in the United Kingdom, 2019–2040. London: London School of Economics, 2019: 2019–11.
- 4 Nichols E, Steinmetz JD, Vollset SE, *et al*. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. *Lancet Public Health* 2022;7:e105–25.
- 5 Bourne J. Improving services and support for people with dementia. National Audit Office, 2007.
- 6 Morse A. Improving dementia services in England—an interim report. London: National Audit Office, 2010.
- 7 Kane MTG. Dementia 2015: aiming higher to transform lives. London: Alzheimer's Society, 2015.
- 8 Long S, Benoist C, Weidner W. World Alzheimer report 2023: reducing dementia risk: never too early, never too late. London: Alzheimer's Disease International, 2023.
- 9 Department of Health. Prime Minister's challenge on dementia 2020. London: Department of Health, 2015.
- 10 Frost R, Rait G, Aw S, *et al*. Implementing post diagnostic dementia care in primary care: a mixed-methods systematic review. *Ageing Ment Health* 2021;25:1381–94.
- 11 Gauthier SWC, Servaes S, Morais J, *et al*. World Alzheimer report: life after diagnosis: navigating treatment, care and support. London: Alzheimer's Disease International, 2022.
- 12 Robinson EAK. From diagnosis to end of life: the lived experiences of dementia care and support. London: Alzheimer's Disease and the Sowerby Foundation, 2020.
- 13 Prince M, Comas-Herrera A, Knapp MG, *et al*. World Alzheimer report 2016. Improving Healthcare for people living with dementia. coverage, quality and costs now and in the future. 2016.

- 14 Bamford C, Wilcock J, Brunskill G, *et al.* Improving primary care based post-diagnostic support for people living with dementia and Carers: developing a complex intervention using the theory of change. *PLOS ONE* 2023;18:e0283818.
- 15 Skivington K, Matthews L, Simpson SA, *et al.* A new framework for developing and evaluating complex interventions: update of medical research Council guidance. *BMJ* 2021;374:n2061.
- 16 Pearson N, Naylor P-J, Ashe MC, *et al.* Guidance for conducting feasibility and pilot studies for implementation trials. *Pilot Feasibility Stud* 2020;6:167.
- 17 Brooks J, Savitch N, Gridley K. "Removing the 'gag': involving people with dementia in research as advisers and participants". *Soc Res Pract* 2017;3–14.
- 18 Griffiths S, Spencer E, Wilcock J, *et al.* Protocol for the feasibility and implementation study of a model of best practice in primary care led Postdiagnostic dementia care: Pridem. *BMJ Open* 2023;13:e070868.
- 19 Lancaster GA, Thabane L. Guidelines for reporting non-randomised pilot and feasibility studies. *Pilot Feasibility Stud* 2019;5:114.
- 20 Eldridge SM, Chan CL, Campbell MJ, *et al.* CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ* 2016;355:i5239.
- 21 Act. Mental capacity. London Station Office, 2005.
- 22 Bamford C, Wheatley A, Brunskill G, *et al.* Key components of post-diagnostic support for people with dementia and their Carers: A qualitative study. *PLoS One* 2021;16:e0260506.
- 23 NHS England and NHS Improvement. Quality and outcomes framework guidance for 2023/24. *NHS Eng and NHS Improv* 2023.
- 24 England N. Dementia: good care planning – information for primary care and commissioners. 2017.
- 25 Browne RH. On the use of a pilot sample for sample size determination. *Stat Med* 1995;14:1933–40.
- 26 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract* 2004;10:307–12.
- 27 Braun V, Clarke V. Conceptual and design thinking for thematic analysis. *Qual Psychol* 2022;9:3–26.
- 28 May CR, Albers B, Bracher M, *et al.* Translational framework for implementation evaluation and research: a normalisation process theory coding manual for qualitative research and instrument development. *Implement Sci* 2022;17:19.
- 29 O'Shea E, Hopper L, Marques M, *et al.* A comparison of self and proxy quality of life ratings for people with dementia and their Carers: a European prospective cohort study. *Aging Ment Health* 2020;24:162–70.
- 30 Griffiths AW, Smith SJ, Martin A, *et al.* Exploring self-report and proxy-report quality-of-life measures for people living with dementia in care homes. *Qual Life Res* 2020;29:463–72.
- 31 Low LF, Gresham M, Phillipson L. Further development needed: models of post-diagnostic support for people with dementia. *Curr Opin Psychiatry* 2023;36:104–11.
- 32 Vinay R, Biller-Andorno N. A critical analysis of national dementia care guidelines. *Health Policy* 2023;130:S0168-8510(23)00039-8.
- 33 Mountford W, Dening KH, Green J. Advance care planning and decision-making in dementia care: a literature review. *Nurs Older People* 2020;35:5.
- 34 Lopez RP, Wei A, Locke JR, *et al.* Advanced comfort: usability testing of a care planning intervention for nursing home residents in advanced dementia. *J Gerontol Nurs* 2023;49:15–23.
- 35 Bernstein OM, Grill JD, Gillen DL. Recruitment and retention of participant and study partner Dyads in two multinational Alzheimer's disease registration trials. *Alzheimers Res Ther* 2021;13:16.
- 36 Ellison TS, Cappa SF, Garrett D, *et al.* Outcome measures for Alzheimer's disease: a global inter-societal Delphi Consensus. *Alzheimers Dement* 2023;19:2707–29.
- 37 Care NEDoHaS. Delivery plan for recovering urgent and emergency care services. NHS England, 2023.
- 38 Pink J, O'Brien J, Robinson L, *et al.* Dementia: assessment, management and support: summary of updated NICE guidance. *BMJ* 2018;361:k2438.
- 39 Pendlebury ST, Welch SJV, Cuthbertson FC, *et al.* Telephone assessment of cognition after transient ischemic attack and stroke: modified telephone interview of cognitive status and telephone Montreal cognitive assessment versus face-to-face Montreal cognitive assessment and neuropsychological battery. *Stroke* 2013;44:227–9.
- 40 Smith SC, Lamping DL, Banerjee S, *et al.* Development of a new measure of health-related quality of life for people with dementia: DEMQOL. *Psychol Med* 2007;37:737–46.
- 41 Herdman M, Gudex C, Lloyd A, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727–36.
- 42 Cummings JL, Mega M, Gray K, *et al.* The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology (Echronicon)* 1994;44:2308–14.
- 43 Knapp M, Beecham J. Costing mental health services. *Psychol Med* 1990;20:893–908.
- 44 Hoefman RVE, Brouwer WN. iMTA valuation of informal care questionnaire (iVICQ). version 1.0 IBMG/iMTA. 2011.
- 45 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
- 46 Brown A, Page TE, Daley S, *et al.* Measuring the quality of life of family Carers of people with dementia: development and validation of C-DEMQOL. *Qual Life Res* 2019;28:2299–310.
- 47 Devlin NJ, Shah KK, Feng Y, *et al.* Valuing health-related quality of life: an EQ-5D-5L value set for England. *Health Econ* 2018;27:7–22.